NY-MEDICREA
20.9.2018 15:09:05 CEST | Business Wire | Press release
The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED, PEA-PME eligible, and OTCQX: MNRTY and MNRTF), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) technology, announced today that the Company is attending the Eurospine 2018 meeting taking place in Barcelona, Spain, from September 19th to 21st , where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology.
Denys Sournac, President and Chief Executive Officer, stated, “At Eurospine 2018, our team of biomedical engineers will show attending spine surgeons how the UNiD™ASI technology answers the gap left by traditional implant manufacturers through a demonstration of the UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to each individual patient and at the same time to each individual surgeon technique.”
Five years after its initial launch in September 2013, over 2,800 patients have benefited from UNiD™ ASI 100% proprietary pre-operative planning technologies and services associated with patient-specific spinal realignment rods, with a strong acceleration in adoption rate in 2018 (+60% cases in year-to-date 2018) especially in the USA.
Since its inception, the technology supported surgeons specializing in adult indications with planning services and patient-specific implants focused on restoring sagittal alignment. More recently, surgeons have found the technology to be fully applicable to the pediatric population as well. As such, surgeons have increasingly published on the application of UNiD™ ASI in pediatrics and have begun to demonstrate the importance of respecting sagittal parameters in the pediatric population.
Jean-Luc Clément, M.D. of Fondation Lenval (Nice, FRANCE) and UNiD™ASI user recently published the Article titled “Surgical Increase of Thoracic Kyphosis Increases Unfused Lumbar Lordosis in Selective Fusion for Thoracic Adolescent Idiopathic Scoliosis” . In this article, Jean-Luc Clément emphasizes “...the importance of restoring adequate kyphosis and respecting the links between sagittal parameters (thoracic kyphosis, lumbar lordosis and pelvic incidence) specifically in adolescent surgery. A task which is close to impossible for a surgeon without the appropriate tools that are now provided by Medicrea through UNID™ ASI Platform. Data analytics and predictive modeling are topics that surgeons and healthcare professionals recognize will shape the future of care and the way we view spine surgery.”
The recent publication by Jean-Luc Clément, M.D. et al. hypothesizes that correction of hypokyphosis in AIS increases lumbar lordosis, especially its proximal part by reciprocal changes. The study involves 111 patients selectively instrumented using the ST2R technique on the thoracic region with 2 years of follow-up. The author demonstrates and evaluates that non-instrumented lumbar lordosis was directly increased and proportionally impacted by the thoracic kyphosis correction.
Jean-Luc Clément also stated, “These results are supporting the use of the UNiD™ ASI platform to obtain the expected patient-specific thoracic kyphosis to adapt lumbar lordosis to the patient’s specific pelvic incidence.”
Medicrea’s proprietary UNiD™ ASI technology and services integrates numerous proprietary predictive models, one of which takes into consideration the post-operative compensatory mechanisms occurring on the non-instrumented portion of the spine both above and below the construct. Through the UNiD™ HUB, the algorithms use large amounts of data to generate intelligent surgical planning through machine learning while simultaneously allowing the surgeon to perform detailed, custom analysis of the cases. Medicrea uses proprietary data science to drive improved outcomes and economic efficiencies in spine surgery.
Meeting attendees are invited to learn more about Medicrea at Booth 33B.
About Medicrea (www.medicrea.com)
Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.
For further information, please visit: Medicrea.com.
Connect with Medicrea
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE
Medicrea
is listed on
EURONEXT Growth Paris
ISIN:
FR 0004178572
Ticker:
ALMED
LEI:
969500BR1CPTYMTJBA37
Medicrea is traded on
OTCQX Best Market
Tickers:
MNRTY & MRNTF
View source version on businesswire.com: https://www.businesswire.com/news/home/20180920005476/en/
Contact:
Medicrea Denys Sournac Founder, Chairman and CEO dsournac@medicrea.com or Fabrice Kilfiger, +33 (0)4 72 01 87 87 Chief Financial Officer fkilfiger@medicrea.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom